Patients suffering from inherited primary immune deficiencies (PIDs) are prone to infections and a high risk of cancer. European research is developing new tools based on gene therapy to build a healthy immune system.
Treatment with genetically modified haematopoietic stem cells (HSCs) for patients with PIDs has already been successful. However, safety issues exist in relation to viral vectors of the genes.
Further details: Cell therapy for immunodeficiency